Synthetic lethality and synergetic effect: the effective strategies for therapy of IDH-mutated cancers
Mutant isocitrate dehydrogenase 1/2 (mIDH1/2) gain a novel function for the conversion of α-ketoglutarate (α-KG) to oncometabolite R-2-hydroxyglutarate (R-2-HG). Two molecular entities namely enasidenib (AG-221) ...
Source: Journal of Experimental and Clinical Cancer Research - Category: Cancer & Oncology Authors: Kun Yao, Hua Liu, Jiajun Yin, Jianmin Yuan and Hong Tao Tags: Review Source Type: research
More News: Cancer | Cancer & Oncology